Ketamine Biomarker Validation

StatusWithdrawn
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Withdrawn before enrolling Sponsor's reason: Funding was not provided Show 5 more changesShow less
    • Enrollment target: estimated 20 to confirmed 0
    • Interventions: Ketamine (0.25 mg/kg) (Drug), Ketamine (0.5 mg/kg) (Drug), Ketamine (0.75 mg/kg) (Drug) to Ketamine (0.25 mg/kg) (Drug), Ketamine (0.5 mg/kg) (Drug), Ketamine (0.75 mg/kg) (Drug)
    • Eligibility criteria expanded, about 10 words
    • Site contact updated
    • Study description shortened, about 1 word
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
Soterix Medical
3 trials monitored
See 1 trial at risk
Depression
3,069 trials monitored
See 170 trials at risk
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
Trial Details
NCT Number NCT07307768
Lead Sponsor Soterix Medical
Collaborators: Columbia University
Conditions
(from sponsor)		 Treatment Resistant Depression (TRD)
Related terms Depression, Depressive Disorder, Depressive Disorder, Treatment-Resistant
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov